Morgan Stanley began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $29.00 target price on the stock.
Separately, Bank of America initiated coverage on Fulcrum Therapeutics in a report on Monday. They issued a buy rating and a $19.00 price target on the stock.
Shares of Fulcrum Therapeutics stock opened at $9.26 on Monday. Fulcrum Therapeutics has a one year low of $9.25 and a one year high of $15.94.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Featured Article: Dollar Cost Averaging
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.